858-Engineered Dendritic Cells for Cardiac Remodelling
The paper detail the development and testing of engineered immunosuppressive and fibrosis-targeted dendritic cells (iCDCs) as a novel treatment for heart failure. These specialized cells are designed to home specifically to damaged heart tissue by targeting fibroblast activation protein (FAP), where they deliver a combination of immunomodulatory factors including IL-10, CTLA4-Ig, and PD-L1. Experimental results in mouse and non-human primate models show that this therapy effectively reduces pathological cardiac fibrosis, enhances blood flow, and preserves heart muscle contractility after…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.